Literature DB >> 12819474

Mechanisms of glucocorticoid-induced osteoporosis.

Ernesto Canalis1.   

Abstract

Glucocorticoids modify osteoblastic cell differentiation, number, and function. Glucocorticoids stimulate osteoclastogenesis and increase the expression of receptor activator of Nuclear factor-kappaB ligand and colony-stimulating factor-1, and decrease the expression of osteoprotegerin. However, the most significant effect of glucocorticoids in bone is an inhibition of bone formation. This inhibition is caused by a decrease in the number of osteoblasts secondary to a shift in the differentiation of mesenchymal cells away from the osteoblastic lineage, and an increase in the death of mature osteoblasts. Glucocorticoids decrease the function of the remaining osteoblasts directly and indirectly through the inhibition of insulin-like growth factor I expression. The stimulation of bone resorption is likely responsible for the initial bone loss after glucocorticoid exposure. Eventually, the inhibition of bone formation will cause a decrease in bone remodeling and a continued increased risk of fractures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819474     DOI: 10.1097/00002281-200307000-00013

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  36 in total

Review 1.  Genetic regulation of bone mass: from bone density to bone strength.

Authors:  Craig B Langman
Journal:  Pediatr Nephrol       Date:  2005-01-05       Impact factor: 3.714

2.  The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids.

Authors:  Guoqiang Hua; Naimah Zein; Laetitia Paulen; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-20       Impact factor: 11.205

3.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

Review 4.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

5.  Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.

Authors:  Maobin Yang; Lorin B Trettel; Douglas J Adams; John R Harrison; Ernesto Canalis; Barbara E Kream
Journal:  Bone       Date:  2010-06-09       Impact factor: 4.398

Review 6.  Tissue engineered bone mimetics to study bone disorders ex vivo: Role of bioinspired materials.

Authors:  Yuru Vernon Shih; Shyni Varghese
Journal:  Biomaterials       Date:  2018-06-06       Impact factor: 12.479

7.  Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation.

Authors:  Zahia Hamidouche; Olivia Fromigué; Jochen Ringe; Thomas Häupl; Pierre J Marie
Journal:  BMC Cell Biol       Date:  2010-06-23       Impact factor: 4.241

8.  Prevalence and risk factors of vertebral compression fractures in female SLE patients.

Authors:  Katarina Almehed; Szabolcs Hetényi; Claes Ohlsson; Hans Carlsten; Helena Forsblad-d'Elia
Journal:  Arthritis Res Ther       Date:  2010-08-02       Impact factor: 5.156

9.  Vitamin D in nephrotic syndrome remission: a case-control study.

Authors:  Sushmita Banerjee; Surupa Basu; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2013-05-25       Impact factor: 3.714

10.  Large increases in adipose triacylglycerol flux in Cushingoid CRH-Tg mice are explained by futile cycling.

Authors:  Charles Harris; Donald J Roohk; Mark Fitch; Benjamin M Boudignon; Bernard P Halloran; Marc K Hellerstein
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-04       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.